Protagonist Therapeutics, Inc. (PTGX) - Q2 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2026. Protagonist Therapeutics is a biopharmaceutical company focused on peptide therapeutics in inflammation/immunology, hematology, and metabolic diseases. Key assets include ICOTYDE (icotrokinra), approved in the U.S. in March 2026 for plaque psoriasis and licensed to Janssen (JNJ), and rusfertide, a hepcidin mimetic for polycythemia vera (PV) licensed to Takeda, with an NDA under FDA priority review.
Key Financial Metrics (Six Months Ended June 30, 2026)
| Metric | Value (in thousands) |
|---|---|
| License and Collaboration Revenue | $269,843 |
| Net Income | $166,632 |
| Operating Expenses | $114,725 |
| Cash, Cash Equivalents, and Marketable Securities | $849,500 |
| Net Cash Provided by Operating Activities | $170,109 |
| Accumulated Deficit | $(304,039) |
| Shares Outstanding (July 31, 2026) | 64,708,285 |
Material Changes vs. Prior Period
- Revenue Surge: Revenue increased from $33.9 million in the prior year period to $269.8 million. This was driven by a $50.0 million milestone from JNJ for ICOTYDE approval and the recognition of $192.4 million related to the Takeda opt-out payment.
- Profitability Shift: The company reported a net income of $166.6 million, a significant turnaround from a net loss of $46.4 million in the same period in 2025.
- Liquidity Expansion: Total cash and marketable securities grew from $646.0 million at year-end 2025 to $849.5 million, bolstered by collaboration payments.
- Expense Growth: R&D expenses rose 22% to $88.8 million, primarily due to the advancement of the PN-881 program and pre-clinical discovery, partially offset by reduced rusfertide costs following the Phase 3 trial completion.
Guidance, Outlook, and Material Events
- Takeda Opt-Out: In April 2026, Protagonist exercised its right to opt out of the U.S. profit-sharing arrangement with Takeda. This triggered a $200.0 million payment (received in Q2) and eligibility for an additional $200.0 million opt-out fee and $75.0 million milestone upon FDA approval of rusfertide. Future royalties range from 14% to 29%.
- Rusfertide Approval: The FDA granted Priority Review for rusfertide with a target action date in August 2026. Takeda expects a launch in H2 2026 if approved.
- Pipeline Progress: ICOTYDE is in Phase 3 for psoriatic arthritis and ulcerative colitis. New candidates PN-881 (IL-17), PN-477 (obesity triple agonist), and PN-458 (obesity dual agonist) are advancing into clinical development.
- Capital Runway: Management states existing cash resources are sufficient to fund operations for at least the next 12 months. No immediate need for additional funding is anticipated.
- Risks: Key risks include the commercial success of rusfertide depending on Takeda's efforts, potential impact of new U.S. tariffs on pharmaceutical imports (effective July 31, 2026), and the inherent uncertainties of clinical development.
Investor Verification Checklist
- Verify the timing and conditions of the remaining $275.0 million in Takeda payments (opt-out fee and approval milestone) contingent on the August 2026 FDA decision.
- Confirm the commercial launch timeline for ICOTYDE by Janssen and the trajectory of royalty revenue recognition.
- Assess the impact of the 100% tariff threat on imported pharmaceuticals announced in April 2026 on future manufacturing costs and supply chains.
- Monitor the progression of the PN-881 Phase 2b program and the initiation of Phase 1 studies for obesity candidates PN-477 and PN-458.
- Review the specific accounting treatment of the Takeda opt-out revenue recognition to ensure sustainability of future earnings.